Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Anna Polakiewicz-Gilowska"'
Autor:
Marcin Kubeczko, Anna Polakiewicz-Gilowska, Katarzyna Świderska, Aleksandra Leśniak, Marta Mianowska-Malec, Barbarba Łanoszka, Konstanty Chomik, Barbara Grandys, Natalya Lisovska, Barbara Bobek-Billewicz, Ewa Chmielik, Michał Jarząb
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundCyclin-dependent kinase 4/6 inhibitors (CDK4/6i) represent the gold standard of the hormone receptor positive human epidermal growth factor receptor 2 (HER-2) negative advanced breast cancer. However, optimal treatment after disease progres
Externí odkaz:
https://doaj.org/article/9a4c366505004ce28c0ef2c9cfb629a9
Autor:
Marcin Kubeczko, Dorota Gabryś, Anna Polakiewicz-Gilowska, Barbara Bobek-Billewicz, Michał Jarząb
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 927 (2024)
Background. The use of locoregional radiotherapy (RT) in patients with advanced ER-positive, HER2-negative breast cancer remains a topic of ongoing debate. In this study, we aimed to evaluate the efficacy of locoregional RT in advanced breast cancer
Externí odkaz:
https://doaj.org/article/a6a356455bfc4010aa9722dfc8768f5e
Autor:
Michał Jarząb, Ewa Stobiecka, Agnieszka Badora-Rybicka, Ewa Chmielik, Małgorzata Kowalska, Wiesław Bal, Anna Polakiewicz-Gilowska, Barbara Bobek-Billewicz, Dariusz Lange, Rafał Tarnawski
Publikováno v:
Polish Journal of Pathology, Vol 70, Iss 2, Pp 91-99 (2019)
Currently, breast cancer chemotherapy response can be predicted based on various parameters, with common reporting of tumour grade and Ki67 proliferation index. We analysed their association with pathological complete response (pCR) in a multivariate
Externí odkaz:
https://doaj.org/article/54e543275bb84b828e304162f0be70c2
Autor:
Marcin Kubeczko, Anna Michalik, Agnieszka Badora-Rybicka, Anna Polakiewicz-Gilowska, Andrea d'Amico, Michał Kalemba, Aleksandra Leśniak, Katarzyna Świderska, Marta Mianowska-Malec, Agnieszka Pasierbek, Barbara Łanoszka, Konstanty Chomik, Barbara Bobek-Billewicz, Michał Jarząb
Publikováno v:
Cancer Research. 82:P2-12
Introduction. The addition of carboplatin to standard neoadjuvant chemotherapy (NAC) including dose-dense (dd) anthracycline-cyclophosphamide (AC) combination followed by taxanes in triple negative breast cancer (TNBC) is the most intense routinely u
Autor:
Marcin Kubeczko, Michał Jarząb, Aleksandra Krzywon, Donata Gräupner, Anna Polakiewicz-Gilowska, Dorota Gabryś
Publikováno v:
Journal of Clinical Medicine
Volume 12
Issue 5
Pages: 2044
Volume 12
Issue 5
Pages: 2044
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are the standard of care for HR-positive/HER2-negative advanced breast cancer patients. However, their role in the treatment of brain metastases is currently unclear. We
Autor:
Marcin Kubeczko, Dorota Gabryś, Marzena Gawkowska, Anna Polakiewicz-Gilowska, Alexander J. Cortez, Aleksandra Krzywon, Grzegorz Woźniak, Tomasz Latusek, Aleksandra Leśniak, Katarzyna Świderska, Marta Mianowska-Malec, Barbara Łanoszka, Konstanty Chomik, Mateusz Gajek, Anna Michalik, Elżbieta Nowicka, Rafał Tarnawski, Tomasz Rutkowski, Michał Jarząb
Publikováno v:
Cancers
Volume 15
Issue 3
Pages: 690
Volume 15
Issue 3
Pages: 690
The addition of CDK4/6 inhibitors to endocrine therapy in advanced hormone receptor-positive HER2-negative breast cancer has led to practice-changing improvements in overall survival. However, data concerning the safety of CDK4/6i combination with ra
Autor:
Thomas Powles, Michiel S van der Heijden, Daniel Castellano, Matthew D Galsky, Yohann Loriot, Daniel P Petrylak, Osamu Ogawa, Se Hoon Park, Jae-Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J Eigl, Howard Gurney, Som D Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P Fay, Ignacio Duran, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok K Gupta, Wendy Levin, Joaquim Bellmunt, Michiel S. van der Heijden, Jae Lyun Lee, Bernhard J. Eigl, Som D. Mukherjee, Cristina Suarez, Hans Westgeest, Aude Flechon, Yen-Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez-Valderrama, Susanna Cheng, Stephen Frank, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala Sridhar, Giorgio Vittorio Scagliotti, Jens Voortman, Boris Alekseev, Anna Alyasova, Boris Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, Jose Angel Arranz, Djura Piersma, Sang Joon Shin, Oleg Karyakin, Ignacio Delgado, Jose Luis Gonzalez, See-Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, Monserrat Domenech, Yen-Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, Vasileios Georgoulias, Sasja Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott Tagawa, Pawel Zalewski, Florence Joly, Gencay Hatiboglu, Luca Gianni, Franco Morelli, Rosa Tambaro, Yasuhiro Hashimoto, Alexander Nosov, Albert Font, Alejo M. Rodriguez-Vida, Robert Jones, Naveen Vasudev, Sandhya Srinivas, Jingsong Zhang, Thierry Gil, Daygen Finch, Marc-Oliver Grimm, Yu-Li Su, Simon Chowdhury, Christopher Hocking, Eugen Plas, Scott North, Niels Viggo Jensen, Christine Theodore, Florian Imkamp, Avivit Peer, Takashi Kobayashi, Hideki Sakai, Naoto Sassa, Kazuhiro Yoshimura, Maureen Aarts, Ana Ferreira Castro, Marlen Topuzov, Juan Francisco Rodriguez, Federico Jose Vazquez, Yu-Chieh Tsai, Simon Crabb, Syed Hussain, Johanna Bendell, Marine Gross-Goupil, Gravis Gwenaelle, Raanan Berger, Galina Statsenko, Linda Evans, Alexandra Drakaki, Bradley Somer, Ian Davis, James Lynam, Giuliano Borges, Aldo Dettino, André P. Fay, Graziella Martins, Luis Eduardo Zucca, Mads Agerbaek, Haralambos Kalofonos, Eli Rosenbaum, Hideki Enokida, Hiroaki Kikukawa, Kazuo Nishimura, Satoshi Tamada, Motohide Uemura, Yamil Lopez, Jourik Gietema, Marcin Slojewski, Isabel Fernandes, Alexey Smolin, Danish Mazhar, Arash Rezazadeh Kalebasty, Bradley Carthon, Wolfgang Loidl, Fabio Franke, Gustavo Girotto, Nimira Alimohamed, Robyn Macfarlane, Helle Pappot, Guenter Niegisch, Dimitrios Mavroudis, Avishay Sella, Camillo Porta, Shin Ebara, Motonobu Nakamura, Wataru Obara, Norihiko Okuno, Nobuo Shinohara, Mikio Sugimoto, Akitaka Suzuki, Noriaki Tokuda, Hiroji Uemura, Akito Yamaguchi, Francisco Ramirez, Pawel Rozanowski, Pawel Wiechno, Bhumsuk Keam, Nikolay Kislov, Denis Plaksin, Irfan Cicin, Satish Kumar, Matthew D. Galsky, Daniel P. Petrylak, Joseph Rosales, Ulka Vaishampayan, Stephane Culine, Christos Papandreou, Taketoshi Nara, Mustafa Erman, Laurence Kreiger, Juliana Janoski, Diogo Rosa, Mariana Siqueira, Christina Canil, Lisa Sengelov, Jean-Marc Tourani, Gaku Arai, Katsuyoshi Hashine, Mutsushi Kawakita, Noboru Nakaigawa, Hayahito Nomi, Hiroaki Shiina, Hiroyoshi Suzuki, Junji Yonese, Roberto Kuri, Eleazar Macedo, Samuel Rivera, Alberto Villalobos Prieto, Anna Polakiewicz-Gilowska, Renata Zaucha, Fabio Lopes, Roman Ponomarev, Mark Pomerantz, Shahrokh Shariat, Cynthia Luk, Krzysztof Lesniewski-Kmak
Publikováno v:
lancet oncology, 21(12), 1574-1588. Lancet Publishing Group
Lancet Oncology, 21(12), 1574-1588. Lancet Publishing Group
DANUBE study investigators & Voortman, J 2020, ' Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial ', Lancet Oncology, vol. 21, no. 12, pp. 1574-1588 . https://doi.org/10.1016/S1470-2045(20)30541-6
The Lancet Oncology, 21(12), 1574-1588. ELSEVIER SCIENCE INC
Lancet Oncology, 21(12), 1574-1588. Lancet Publishing Group
DANUBE study investigators & Voortman, J 2020, ' Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial ', Lancet Oncology, vol. 21, no. 12, pp. 1574-1588 . https://doi.org/10.1016/S1470-2045(20)30541-6
The Lancet Oncology, 21(12), 1574-1588. ELSEVIER SCIENCE INC
Background: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or
Autor:
Marco Di Pietro, Anna Michalik, Anna Polakiewicz-Gilowska, Agnieszka Pasierbek, Rafal Tarnawski, Marcin Kubeczko, Damian Borys, Agnieszka Badora-Rybicka, Andrea d'Amico, Mateusz Raus, Barbara Bobek-Billewicz, Michał Jarząb, Wiesław Bal, Olgierd Chrabański, Izabela Gorczewska
Publikováno v:
Cancer Research. 80:P4-02
Preoperative chemotherapy (preopCT) is gaining importance in management of breast cancer, as it allows to avoid axillary clearance in responders. In case of axillary surgery the pathological complete response (pCR) of involved nodes is required to om
Autor:
Anna Polakiewicz-Gilowska, Danuta Starzyczny-Słota, Beata Kaleta, Dominika Leś, Elżbieta Nowara
Publikováno v:
OncoReview. 5:16-20
Autor:
Magdalena Kustra, Anna Drosik, Anna Polakiewicz-Gilowska, Elżbieta Nowara, Agnieszka Boratyn-Nowicka, Joanna Huszno
Publikováno v:
Contemporary Oncology
Gastric cancer is one of the most frequent neoplasms. Although the incidence of gastric cancer worldwide has declined, there is still high mortality. Treatment of inoperable disease is under evaluation in clinical trials. In palliative treatment chem